Gluten Intolerance Treatment Market Share

  • Report ID: 5081
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Gluten Intolerance Treatment Industry - Regional Synopsis

European Market Forecast

Europe industry is predicted to dominate majority revenue share of 34% by 2037, due to increasing review of the broad spectrum of gluten-related disorders, with focused clinical investigations, diagnostic criteria, and therapeutic approaches for different conditions causing gluten intolerance.The increasing review of the broad spectrum of gluten-related disorders, with focused clinical investigations, diagnostic criteria, and therapeutic approaches for different conditions causing gluten intolerance will drive its treatment market in the region.

The prevalence of celiac disease, primarily in Northern European, specifically, in countries like Finland that have a relatively high rate of this condition is gradually leading the region towards improved methods of diagnosis and recognition and treatment of such conditions, bolstering the regional market expansion. Nearly 2.5% of all adults between the ages of 30 and 64 have been diagnosed with celiac disease in Finland.

APAC Market Statistics

The Asia Pacific region is projected to account for 25% of the overall gluten intolerance treatment market share by 2037. The growing concern about gluten intolerance that is on the rise among Asians, especially among the population of China and India is anticipated to boost the market demand in the region.

China and India are the most populous countries in the world and the increasing evolution of modern farming practices for wheat cultivation, with advancements in food processing, has resulted in higher gluten content in wheat which is considered a major factor that will lead to the higher incidence of gluten intolerance in the region.

Gluten Intolerance Treatment Market Size

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of gluten intolerance treatment is assessed at USD 1.03 billion.

The gluten intolerance treatment market size was over USD 842.52 million in 2024 and is projected to reach USD 4.52 billion by 2037, witnessing around 13.8% CAGR during the forecast period i.e., between 2025-2037. The growing prevalence of autoimmune, allergic, and non-autoimmune-allergic GRDs and the rising damage of gut flora will boost the market growth.

Europe industry is predicted to dominate majority revenue share of 34% by 2037, due to increasing review of the broad spectrum of gluten-related disorders, with focused clinical investigations, diagnostic criteria, and therapeutic approaches for different conditions causing gluten intolerance.

The major players in the market are Takeda Pharmaceutical Company Limited, ActoBio Therapeutics, Inc., Precigen, Inc., Calypso Biotech BV, ImmunogenX, Inc., Alvine Pharmaceuticals, Dr. Falk Pharma GmbH, ImmusanT, Inc., Zedira GmbH, FunZyme BioTechnologies S.A., Amyra Biotech AG
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos